Form 4 for SABS SAB Biotherapeutics, Inc.

Accepted 2021-10-05 00:00:00 ET · period of report 2021-10-01 · accession 0001493152-21-024640 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2021-10-05	2021-10-01	SABS	Katz Ilan	Dir, 10%	P - Purchase	$10.09	+1,000	1,000	New	+$10.1K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-10-01	P	A	1,000	$10.09	1,000	D	—	—	(F2) Includes 3,047,825 shares of the issuer's common stock held directly by Big Cypress Holdings LLC (the "Sponsor") and indirectly by Samuel J. Reich and Ilan Katz as managers of the Sponsor, which includes 417,200 private placement units of the issuer. The private placement units were purchased in a private placement that closed simultaneously with the closing of the issuer's initial public offering, and each such unit consists of one share of common stock of the issuer and one-half of one warrant of the issuer. The warrants included in the units will become exercisable, if at all, on the later of 30 days after the completion of the issuer's initial business combination and 12 months from the closing of the issuer' initial public offering.